Article Text

Download PDFPDF

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
  1. David Smith1,
  2. Ingrid A Du Rand2,
  3. Charlotte Addy3,
  4. Timothy Collyns4,
  5. Simon Hart5,
  6. Philip Mitchelmore6,
  7. Najib Rahman7 and
  8. Ravijyot Saggu8
  1. 1North Bristol Lung Centre, Southmead Hospital, Bristol, UK
  2. 2Respiratory, Wye Valley NHS Trust, Hereford, UK
  3. 3Centre for Medical Education, Queens University Belfast, Regional Respiratory Centre, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, UK
  4. 4Medical Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  5. 5Cardiovascular and RespiratoryStudies, Hull York MedicalSchool/University of Hull, Hull, UK
  6. 6Institute of Biomedical and Clinical Science, College of Medicine & Health, University of Exeter, Department of Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
  7. 7Oxford Respiratory Trials Unit, University of Oxford, Oxford NIHR Biomedical Research Centre, Oxford, UK
  8. 8Pharmacy, University College London, London, UK
  1. Correspondence to Dr David Smith; david.smith{at}nbt.nhs.uk

Abstract

The full British Thoracic Society (BTS) guideline for the use of long-term macrolides in adults with respiratory disease is published in Thorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline. The appendices are available in the full guideline and online appendices are available on the BTS website. This is the first BTS guideline to use the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach as part of the process of guideline development and the guideline was used to pilot the new methodology.

  • respiratory infection
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors DS and IDR chaired the Guideline Group, and as lead authors led the drafting and revision of the document. All the authors drafted sections of the full guideline and undertook revisions of the paper. DS and IDR had final responsibility for the guideline and the summary paper submitted to BMJORR.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests CA, TC, IDR, PM, DS and RS had no funding to declare. SH declared funding from Chiesi. NR declared funding from Rocket Medical, UK, Lung Therapeutics and BD.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data availability statement There are no data in this work.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.